TECOS, Merck’s Cardiovascular Safety Trial of JANUVIA (sitagliptin), Met Primary Endpoint in Patients with Type 2 Diabetes

Dateline City: KENILWORTH, N.J. Findings Published in the New England Journal of Medicine and Presented at the American Diabetes Association Scientific Sessions Treatment with Sitagliptin Did Not Increase the Risk of Major Adverse Cardiovascular Events in the Primary Composite Endpoint, or Hospitalization for Heart Failure, Compared with Placebo KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the primary results of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS), a placebo-controlled study of the cardiovascular (CV) safety of Merck’s DPP-4 inhibitor, JANUVIA® (sitagliptin), added to usual care in more than 14,000 patients. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Joe Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Media Capsule: Please Activate Javascript !function(d, s, id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?'http':'https',dt=new Date().getTime();if(!d.getElementById(id))...
Source: Merck.com - Product News - Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news